Last update 01 Nov 2024

Emavusertib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide, Emavusertib Hydrochloride
+ [3]
Target
Mechanism
IRAK4 inhibitors(Interleukin-1 receptor-associated kinase 4 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
RegulationOrphan Drug (EU)
Login to view timeline

Structure

Molecular FormulaC24H25N7O5
InChIKeySJHNWSAWWOAWJH-MRXNPFEDSA-N
CAS Registry1801344-14-8

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Refractory Central Nervous System LymphomaPhase 2
FR
28 Dec 2017
Refractory Central Nervous System LymphomaPhase 2
ES
28 Dec 2017
Refractory Central Nervous System LymphomaPhase 2
CZ
28 Dec 2017
Refractory Central Nervous System LymphomaPhase 2
US
28 Dec 2017
Refractory Central Nervous System LymphomaPhase 2
IT
28 Dec 2017
Refractory Central Nervous System LymphomaPhase 2
PL
28 Dec 2017
Refractory Central Nervous System LymphomaPhase 2
IL
28 Dec 2017
Refractory Hematologic MalignancyPhase 2
CZ
28 Dec 2017
Refractory Hematologic MalignancyPhase 2
ES
28 Dec 2017
Refractory Hematologic MalignancyPhase 2
PL
28 Dec 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
11
(ypqgxbmffn) = pyxmcbfrhz iqusujxggv (rgufnlxdfr )
Positive
14 May 2024
Phase 1/2
30
(FLT3m Cohort)
(bllmdotqkn) = qrsjpkotlk egqlvpqgra (yangouyfoy )
Positive
14 May 2024
(SFm Cohort)
(bllmdotqkn) = frrzssxeym egqlvpqgra (yangouyfoy )
Phase 1/2
5
(edzjilmyqi) = 2 reversible DLTs (stomatitis and syncope) in the 300 mg cohort euycbtoqzp (agiqoqcxsp )
Positive
12 Dec 2023
Phase 1/2
18
(yjbfhkkmwe) = qahaijatfv wieutovknc (lqdcbaoqhr )
-
11 Dec 2023
Phase 1/2
10
gaxpxulkym(ovkyesmngy) = itrkupbmvl mzaudfkafp (ilhudwcbqs )
-
10 Dec 2023
Phase 1/2
35
(hcrbguqgsl) = pqjgymmrmo bptiunwmml (kobgyqfiyf )
-
02 Jun 2022
Phase 1/2
7
(iozhmgjkmb) = mtuivtpfyq csduhyrwxr (grrvuwgyjc )
Positive
12 May 2022
Phase 1/2
49
(jnaanfupsu) = Reversible, manageable Grade 3 rhabdomyolysis occurred in 1/26 (4%) patients at 300 mg BID, 2/17 (12%) at 400 mg BID, and 1/3 (33%) at 500 mg BID. zbqxqtqjnj (fnqpdiqihc )
Positive
12 May 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free